Head Genetics Inc. presents itself as a Nashville-based biotech startup aiming to reinvent concussion diagnostics with an at-home saliva test. The company publicly promotes a consumer-friendly kit paired with an AI-assisted telehealth review that, in theory, could help coaches, parents, and medical professionals detect traumatic brain injuries more quickly. Head Genetics markets the product as an accessible tool that uses “FDA-approved materials” and positions itself within a multibillion-dollar market for concussion assessment.
The founders, George Gallo and Fabian Maclaren, describe themselves as experienced operators. Gallo’s background centers on branding, packaging, and commercial design for national consumer companies. Maclaren claims more than a decade in biotechnology and pharmaceuticals, including previous leadership roles and what he described to investors as a “$500 million exit.” These credentials were central to the story that convinced investors the company was poised for rapid scale.
Now, two investment firms say the entire foundation of that story appears to be inaccurate.
The Lawsuit: Allegations of Fabricated Timelines and Misrepresented Progress
Solidaris Capital LLC and Cirrus Investments LLC have sued Head Genetics, Carita Investments LLC, and individual defendant Mark Bianchi, alleging that the company misled them during a fundraising effort structured as the “Tech2head Recovery” charitable-deduction securities offering. According to the complaint, nearly every cornerstone of Head Genetics’ narrative breaks down under scrutiny.
The most striking allegation involves the development timeline. Investors say they were told the saliva-testing technology had been under development since 2013. Incorporation records, however, show that Head Genetics was formed in 2022. Plaintiffs argue that a claimed decade of R&D that cannot be verified is not a minor discrepancy but a fundamental misrepresentation in a medical-device investment.
Court documents also state that searches of FDA databases revealed no submissions, no applications, and no regulatory filings by Head Genetics. Despite this, marketing materials referenced “FDA approved” elements of the kit, phrasing that appears—according to the lawsuit—to create the misleading impression that the device itself has achieved FDA review.
The complaint goes further. It claims that:
- Head Genetics has no registered clinical trials
- No peer-reviewed research or validation studies exist
- Key founder biography claims appear unconfirmed by public business records
- Money raised through the offering may have moved through several intermediary entities with minimal visibility
The investors argue that the combination of an unverifiable timeline, a lack of regulatory progress, and the absence of scientific evidence collectively point to a company that has not demonstrated the fundamental legitimacy expected in a biotech venture.
Leadership Under Scrutiny
As part of their due diligence, the plaintiffs attempted to verify Maclaren’s past companies, including Essential Citizen Inc. and Genesis Laboratories Inc. According to filings, neither company provided the documentation investors expected when evaluating claims about major exits or large-scale commercial operations. The lawsuit indicates that searches through corporate transaction databases and industry publications turned up no record of the alleged prior $500 million acquisition.
Gallo’s expertise in branding is not in dispute, but investors claim that his skillset appears disconnected from the scientific and regulatory requirements of bringing a diagnostic medical device to market. Plaintiffs argue that neither founder demonstrated experience with FDA submissions, clinical validation protocols, or medical product commercialization beyond design and marketing.
No Independent Press Coverage Raises More Questions
Analysts following the lawsuit say another issue stands out: the almost complete absence of independent news coverage about Head Genetics. Most medical or sports-related diagnostic breakthroughs generate media attention early in development stages, especially in areas like concussion detection, where demand is high, and public safety is involved.
The fact that Head Genetics has no visible press footprint—from medical trade outlets to local news to sports publications—is increasingly viewed as a warning sign. If the technology were credible, observers argue, athletic trainers, neurologists, or sports organizations would likely have weighed in long before a lawsuit brought the company into the public eye.
Lawsuit Filings Reveal a Complex Financial Structure
The complaint also sheds light on a fundraising process that appears far more complicated than a standard early-stage investment. Solidaris and Cirrus have issued subpoenas to entities including Exemplar Capital LLC, Valiant Strategies Group LLC, and Valiant Investment Holdings LLC. They are seeking records from major financial institutions to trace how funds moved through the Tech2head Recovery structure.
Emergency motions and accelerated discovery requests signal that the plaintiffs believe investor capital may have been distributed through multiple channels, making it harder to determine how much—if any—went toward legitimate product development.
The inclusion of Mark Bianchi as a defendant raises further questions, especially regarding his alleged role in introducing or facilitating the investment. The lawsuit states that Bianchi’s background and due-diligence obligations are now important to understanding how the offering was structured and represented.
Comparisons to Theranos Add Public Pressure
Some analysts and legal observers have begun pointing out similarities to past diagnostic-tech scandals. While the lawsuit does not accuse Head Genetics of anything on the scale of the Theranos collapse, several early warning signs appear similar enough that the comparison is being raised in investor discussions.
Both companies:
- Promoted medical diagnostic technologies without transparent scientific data
- Emphasized visionary marketing over documented clinical evidence
- Relied on founder narratives that could not be independently verified
- Operated without meaningful regulatory filings despite claiming years of development
A recent article on LawyersCorner.com titled “Is Head Genetics the Next Theranos?” highlights growing concern among industry watchers who see a pattern forming. The publication notes that while the allegations remain unproven, the absence of clinical trials, peer-reviewed studies, and FDA approval should prompt heightened scrutiny from investors and regulators.
Why This Case Matters for Investors
Regardless of the lawsuit’s outcome, the filings offer a reminder of how vulnerable even experienced investors can be when evaluating early-stage medical device companies. The combination of plausible science, strong market demand, confident founders, and polished branding can create the illusion of legitimacy even when fundamental evidence is missing.
Industry analysts say the Head Genetics lawsuit illustrates the need for investors to:
- Verify all founder bio claims with independent records
- Confirm development timelines through state filings and IP databases
- Demand FDA documentation rather than accepting references to “approved materials.”
- Search ClinicalTrials.gov for trials tied to the company or its technology
- Request peer-reviewed research when evaluating diagnostic claims
These steps are often overlooked when a company positions itself as nearing commercialization, especially in a field where demand is high and the societal impact is compelling.
What Comes Next
The cases in Texas and Illinois continue to move through the discovery phase, and none of the allegations have yet been proven in court. Head Genetics, Carita Investments, and the individual defendants will have the opportunity to respond as litigation progresses. No regulatory actions or criminal proceedings have been announced.
Still, the lawsuit has brought Head Genetics into far greater public visibility than the company ever generated on its own. As more details emerge, investors, journalists, and industry analysts are paying closer attention to what the filings reveal about both the company’s operations and the broader risks that exist in consumer-facing medical diagnostics.
For now, the lawsuit stands as a cautionary signal. The plaintiffs claim they were misled by a nonexistent timeline, a regulatory path that was never pursued, a product without independent validation, and a leadership narrative that appears inconsistent with public records. Whether the courts agree remains to be seen, but the allegations have already raised essential questions about Head Genetics that the company will eventually have to answer.
